ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) had its price objective cut by analysts at Ascendiant Capital Markets from $27.00 to $25.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target points to a potential upside of 354.55% from the company’s previous close.
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of ENDRA Life Sciences in a report on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, ENDRA Life Sciences has a consensus rating of “Hold” and an average target price of $25.00.
View Our Latest Analysis on ENDRA Life Sciences
ENDRA Life Sciences Price Performance
ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) last released its quarterly earnings results on Friday, May 15th. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.23) by $0.14. Equities analysts anticipate that ENDRA Life Sciences will post -4.65 earnings per share for the current fiscal year.
Hedge Funds Weigh In On ENDRA Life Sciences
An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC acquired a new position in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences accounts for approximately 0.9% of Altium Capital Management LLC’s portfolio, making the stock its 17th largest position. Altium Capital Management LLC owned 6.92% of ENDRA Life Sciences at the end of the most recent reporting period. 1.19% of the stock is owned by institutional investors.
ENDRA Life Sciences Company Profile
ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.
ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.
Read More
- Five stocks we like better than ENDRA Life Sciences
- Burlington Beat Earnings Estimates, But Not Investor Expectations
- Palantir Stock Faces Technical Pressure Despite Strong AI Growth
- These 3 CLO ETFs Target a Niche Corner of the Fixed-Income Market
- 3 Ways to Play the Data Center Land Grab
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.png){kind=logo}